Detailed Narrative
Q2 Financial Performance and Outlook
Moderna reported Q2 FY26 revenue of $145 million, exceeding its guidance range, with a geographic mix of 60% U.S. and 40% international. For the first half, total revenue was $0.5 billion, with 31% from the U.S. and 69% from international markets. The company reiterated its full-year 2026 revenue growth expectation of up to 10%, anticipating a 50-50 U.S. to international split and Q3 revenue representing approximately 55% of H2. Cost discipline continued, with Q2 cash costs reduced by 10% YoY and full-year cost of sales and R&D expense projections lowered to $1.7 billion and $2.9 billion, respectively. The company ended the quarter with $6.9 billion in cash and investments, projecting $4.7 billion to $5.2 billion by year-end 2026.
Respiratory Pipeline Progress
The seasonal flu vaccine, mRNA-1010, received a positive recommendation from the U.S. VRBPAC ahead of its August 5 PDUFA date, with reviews also underway in the EU, Canada, and Australia. Efficacy and safety results were published in the New England Journal of Medicine. For the norovirus vaccine, mRNA-1403, the Phase III study did not meet early success criteria at its interim analysis, leading to plans for an additional fourth cohort enrollment. The company is actively discussing with the FDA the potential for late strain selection updates for flu vaccines, leveraging its rapid mRNA platform capabilities.
Oncology Pipeline Advancements
Moderna's individualized cancer therapy, Intismeran (in partnership with Merck), continues to advance across nine Phase II and Phase III studies. A 5-year Phase II update in adjuvant melanoma highlighted durable clinical benefit, with the Phase III interim analysis expected in 2026. Phase II studies in adjuvant renal cell carcinoma and muscle invasive bladder cancer are fully enrolled, with readouts anticipated in 2026/2027. Dosing has begun in two new cancer antigen therapy programs, mRNA-4200 (solid tumors) and mRNA-4194 (Lynch syndrome), expanding the oncology portfolio beyond Intismeran.
Rare Disease and Other Pipeline Updates
The registrational study for propionic acidemia (PA) is fully enrolled, with data expected in Q4 2026. The decision on a pivotal trial for methylmalonic acidemia (MMA) has been deferred until the PA readouts. Beyond clinical programs, Moderna expanded its partnership with CEPI for an Ebola vaccine and was recognized as the World's Most Impactful Company by Time Magazine for its mRNA science.
Commercial Strategy and Leadership
Moderna's multiyear revenue growth strategy is anchored in geographic and portfolio expansion. mNEXSPIKE is now approved in Japan and Taiwan, and mRESVIA received approval in Mexico and a label expansion in Australia. The company signed a joint procurement contract with the European Commission for up to 24 million doses of mRESVIA. To support this growth, Moderna appointed Ester Banque as Chief Commercial Officer and Michael McDonald to its Board of Directors, strengthening leadership for upcoming product launches and market expansion.